Novozymes’ stock consists of two types: A and B shares, both with a nominal value of DKK 10 per share. All A common stock is held by Novo A/S, and an A share carries 10 times as many votes as a B share.
|A stock||B stock||Total|
|Common stock (DKK)||107,487,200||542,512,800||650,000,000|
|Number of shares||10,748,720||54,251,280||65,000,000|
|Number of votes||1,074,872,000||542,512,800||1,617,384,800|
|Voting rights (%)||66.5||33.5||100|
Novo A/S holds 25.5% of the total outstanding common stock and, through its holding of the A common stock and a proportion (5,826,280) of the B common stock, controls 70.1% of the votes. Novo A/S is fully owned by the Novo Nordisk Foundation, which is why Novozymes is included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Gladsaxe, Denmark.
At the end of 2008 Novozymes had roughly 53,000 shareholders, of which around 98% are private investors, mainly in Denmark. Thirty institutional shareholders own approximately 52% of the B stock (this includes Novozymes A/S’ holding of treasury stock and Novo A/S’ holding). Investors outside Denmark hold approximately 44%.
Novozymes holds 5.6% of the B stock, equivalent to 4.7% of the total number of shares outstanding.
According to the Danish Companies Act, shareholders must notify the company if they hold at least 5% of the company’s common stock. No shareholders, except Novo A/S, hold more than 5% of Novozymes’ common stock.